Fact based stock research
Zynerba Pharmaceuticals (NasdaqGM:ZYNE)


Zynerba Pharmaceuticals stock research in summary

zynerba.com


Zynerba Pharmaceuticals shares have a SELL rating. While they are safely financed, they are bad value, and show below average growth. We recommend selling Zynerba Pharmaceuticals shares.


Latest Obermatt Ranks


Country USA
Industry Pharmaceuticals
Index NASDAQ
Size class X-Small

June 8, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Zynerba Pharmaceuticals

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
15
10
12
STOCK GROWTH RANKS
22
1
1
STOCK SAFETY RANKS
28
60
64
COMBINED STOCK RANKS
5
1
17

Last update of Combined Rank: 8-Jun-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Zynerba Pharmaceuticals in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 8-Jun-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Zynerba Pharmaceuticals; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
1
1
1
PROFIT GROWTH
1
1
1
STOCK RETURNS
97
36
11
CONSOLIDATED RANK: GROWTH
22
1
1

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Zynerba Pharmaceuticals.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
87
92
96
REFINANCING
25
18
16
LIQUIDITY
10
9
27
CONSOLIDATED RANK: SAFETY
28
60
64

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Zynerba Pharmaceuticals and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Zynerba Pharmaceuticals from June 8, 2018.